Summary:
In patients with diabetic foot osteomyelitis (DFO), oral N-acetyl-cysteine (NAC) 600 mg twice daily as an adjuvant therapy significantly accelerated antibiotic responses and reduced infectious inflammatory markers during therapy compared to standard therapy without NAC, though it was associated with minimal side effects.
| PICO | Description |
|---|---|
| Population | Patients diagnosed with diabetic foot osteomyelitis (DFO). |
| Intervention | Oral N-acetyl-cysteine (NAC) 600 mg administered twice daily as an adjuvant to standard therapy. |
| Comparison | Standard therapy without the addition of NAC. |
| Outcome | NAC significantly accelerated antibiotic responses and reduced infectious inflammatory markers during treatment with minimal side effects. The overall trend showed faster improvement in DFO-related infection markers. |
Source: Laya Hooshmand Gharabagh, et al. “Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial.” Read article here.
